Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immix Biopharma, Inc. - Common Stock (NQ:IMMX)

2.180 +0.110 (+5.31%)
Streaming Delayed Price Updated: 2:01 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,438
Open 2.100
Bid (Size) 2.160 (20)
Ask (Size) 2.180 (2)
Prev. Close 2.070
Today's Range 2.100 - 2.190
52wk Range 1.260 - 3.000
Shares Outstanding 27,877,293
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immix Biopharma Attends FDA CEO Forum in Washington DC
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ASCO, Enabling Path to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire

Performance

YTD
-0.9%
-0.9%
1 Month
-16.2%
-16.2%
3 Month
+29.8%
+29.8%
6 Month
-7.6%
-7.6%
1 Year
+2.8%
+2.8%

More News

Read More
The trading volume of these stocks is deviating from the norm in today's session.
Via Chartmill
On Tuesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Discover the top movers in Friday's pre-market session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Thursday's after hours session: top gainers and losers
Via Chartmill
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
From Immix Biopharma, Inc.
Via GlobeNewswire
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
From Immix Biopharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Immix Biopharma, Inc. - Common Stock publicly traded?
Yes, Immix Biopharma, Inc. - Common Stock is publicly traded.
What exchange does Immix Biopharma, Inc. - Common Stock trade on?
Immix Biopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immix Biopharma, Inc. - Common Stock?
The ticker symbol for Immix Biopharma, Inc. - Common Stock is IMMX on the Nasdaq Stock Market
What is the current price of Immix Biopharma, Inc. - Common Stock?
The current price of Immix Biopharma, Inc. - Common Stock is 2.180
When was Immix Biopharma, Inc. - Common Stock last traded?
The last trade of Immix Biopharma, Inc. - Common Stock was at 07/01/25 02:01 PM ET
What is the market capitalization of Immix Biopharma, Inc. - Common Stock?
The market capitalization of Immix Biopharma, Inc. - Common Stock is 60.77M
How many shares of Immix Biopharma, Inc. - Common Stock are outstanding?
Immix Biopharma, Inc. - Common Stock has 61M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.